ESPR — Esperion Therapeutics Balance Sheet
0.000.00%
- $182.30m
- $329.83m
- $332.31m
- 37
- 56
- 33
- 37
Annual balance sheet for Esperion Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 305 | 259 | 167 | 82.2 | 145 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 22.9 | 33.7 | 48.5 | 80.1 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 346 | 329 | 247 | 201 | 338 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7.31 | 2.56 | 1.2 | 4.67 | 5.77 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 353 | 382 | 248 | 206 | 344 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 94.1 | 73.4 | 92.3 | 156 | 246 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 449 | 579 | 572 | 661 | 733 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | -96.1 | -197 | -324 | -455 | -389 |
Total Liabilities & Shareholders' Equity | 353 | 382 | 248 | 206 | 344 |
Total Common Shares Outstanding |